Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.

ClinicalTrials.gov ID: NCT01232283

Public ClinicalTrials.gov record NCT01232283. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis

Study identification

NCT ID
NCT01232283
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Amgen
Industry
Enrollment
413 participants

Conditions and interventions

Interventions

  • Apremilast Drug
  • Placebo Drug
  • Topical or Phototherapy Therapy Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 21, 2010
Primary completion
Mar 14, 2012
Completion
Nov 29, 2016
Last update posted
Mar 14, 2022

2010 – 2016

United States locations

U.S. sites
19
U.S. states
12
U.S. cities
18
Facility City State ZIP Site status
Arizona Skin and Laser Therapy Inst., Ltd. Phoenix Arizona 85023
Burke Pharmaceutical Research Hot Springs Arkansas 71913
Bakersfield Dermatology and Skin Cancer Medical Group Bakersfield California 93309
Dermatology Research Associates Los Angeles California 90045
Clinical Science Institute Santa Monica California 90404
Florida Academic Dermatology Center Miami Florida 33136
Advanced Medical Research Atlanta Georgia 30342
MedaPhase Inc. Newnan Georgia 30263
Northwestern University Northwestern Medical Faculty Foundation Chicago Illinois 60611
Tufts Medical Center Boston Massachusetts 02111
PMG Research of Winston-Salem Winston-Salem North Carolina 27103
Wake Forest University Health Sciences Winston-Salem North Carolina 27104
Clinical Partners, LLC Johnston Rhode Island 02919
Radiant Research, Inc. Anderson South Carolina 29560
Austin Dermatology Associates Austin Texas 78705
Modern Research Associates PLLC Dallas Texas 75231
Center for Clinical Studies Houston Texas 77004
Center for Clinical Studies Webster Texas 77598
Virginia Medical Research Norfolk Virginia 23507

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01232283, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 14, 2022 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01232283 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →